The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib

Saved in:

Bibliographic Details
Published in	Critical care (London, England) Vol. 23; no. 1; pp. 88 - 3
Main Authors	Nyga, Rémy, Simon, Laura, Chouaki, Taieb, Delette, Caroline, Bennis, Youssef, Joseph, Cedric, Marolleau, Jean-Pierre, Slama, Michel, Zogheib, Elie, Maizel, Julien
Format	Journal Article
Language	English
Published	England BioMed Central Ltd 12.03.2019 BioMed Central BMC
Subjects	Aged Antifungal Agents - pharmacokinetics Antifungal Agents - therapeutic use Aspergillosis Aspergillosis - complications Aspergillosis - drug therapy Care and treatment Central nervous system Cerebrum - abnormalities Cerebrum - drug effects Chronic lymphocytic leukemia Drug therapy Humans Ibrutinib Infection Letter Life Sciences Lymphocytic leukemia Male Mycoses Patient outcomes Phenols (Class of compounds) Pyrazoles - pharmacokinetics Pyrazoles - therapeutic use Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use Tyrosine Voriconazole Voriconazole - pharmacokinetics Voriconazole - therapeutic use France
Online Access	Get full text

Loading…